Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Apple Inc (AAPL) vs AbCellera Biologics Inc (ABCL) Price & Performance

AbCellera Biologics IncTrade

Price performance (Past 24H)

Key statistics

Apple Inc vs AbCellera Biologics Inc — how do they compare? Apple Inc trades at $304.99 (market cap $4.50T), while AbCellera Biologics Inc trades at $9.33 (market cap $2.85B). The key difference: Apple Inc is far larger — about 1578.9× AbCellera Biologics Inc's market cap, and Apple Inc pays a 0.35% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

AAPLABCL
Market Cap
$4.50T$2.85B
Volume
100,358,844
Sector
TechnologyHealth
52-Week High
$340.08$9.34
52-Week Low
$224.90$2.78
Enterprise Value
$4.52T$2.45B
Dividend Yield
0.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Apple Inc

AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal but strong fundamentals including a 26.91% net margin and three consecutive quarterly EPS beats. Recent news highlights AI potential via 2.5 billion devices and a Gemini partnership, though store closures and union disputes present headwinds.

The outlook balances robust earnings growth and cash flow against high valuation multiples and technical weakness. Upside to the $337.63 consensus target exists if AI initiatives accelerate, but competition and macroeconomic pressures remain key risks for investors.

AbCellera Biologics Inc

ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.

The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Apple Inc

Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.

Read more on AAPL

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL